Evidence map›Paper›PMID 27275837›Full record

ReviewJournal of clinical medicine2016

Angiogenesis in Ischemic Stroke and Angiogenic Effects of Chinese Herbal Medicine.

Sai-Wang Seto, Dennis Chang, Anita Jenkins, Alan Bensoussan, Hosen Kiat

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 102 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Network pharmacology andPharmaceutical biology · 2022
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sai-Wang SetoNational Institute of Complementary Medicine, Western Sydney University, Locked Bag 1797, Penrith 2751, NSW, Australia. s.seto@westernsydney.edu.au.
Dennis ChangNational Institute of Complementary Medicine, Western Sydney University, Locked Bag 1797, Penrith 2751, NSW, Australia. d.chang@westernsydney.edu.au.
Anita JenkinsNational Institute of Complementary Medicine, Western Sydney University, Locked Bag 1797, Penrith 2751, NSW, Australia. 16292521@student.uws.edu.au.
Alan BensoussanNational Institute of Complementary Medicine, Western Sydney University, Locked Bag 1797, Penrith 2751, NSW, Australia. a.bensoussan@westernsydney.edu.au.
Hosen KiatFaculty of Medicine, University of New South Wales, Sydney 2052, NSW, Australia. hosen.kiat@chi.org.au.
Western Sydney University · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke is one of the major causes of death and adult disability worldwide. The underlying pathophysiology of stroke is highly complicated, consisting of impairments of multiple signalling pathways, and numerous pathological processes such as acidosis, glutamate excitotoxicity, calcium overload, cerebral inflammation and reactive oxygen species (ROS) generation. The current treatment for ischemic stroke is limited to thromolytics such as recombinant tissue plasminogen activator (tPA). tPA has a very narrow therapeutic window, making it suitable to only a minority of stroke patients. Hence, there is great urgency to develop new therapies that can protect brain tissue from ischemic damage. Recent studies have shown that new vessel formation after stroke not only replenishes blood flow to the ischemic area of the brain, but also promotes neurogenesis and improves neurological functions in both animal models and patients. Therefore, drugs that can promote angiogenesis after ischemic stroke can provide therapeutic benefits in stroke management. In this regard, Chinese herbal medicine (CHM) has a long history in treating stroke and the associated diseases. A number of studies have demonstrated the pro-angiogenic effects of various Chinese herbs and herbal formulations in both in vitro and in vivo settings. In this article, we present a comprehensive review of the current knowledge on angiogenesis in the context of ischemic stroke and discuss the potential use of CHM in stroke management through modulation of angiogenesis.

Indexed as

angiogenesiscerebral ischemiaChinese Herbal Medicinestroke

Identifiers

PMID27275837
PMCPMC4929411
OpenAlexW2415128986

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.